ceo call seri life
broader nexsi adopt like remain key
thesi lrp achiev overal like upsid
ebit life exist nexsi convers
ceo seri chri simon ceo seri
weekli call ceo across medic devic field discuss key structur
dynam invest debat recent host chri simon presid
ceo chri tenur outperform
 equip suppli indic respect
compani materi acceler top-line flat msd-hsd
organ growth bottom-line ep declin growth
transform driven new manag heighten focu
effici improv plasma market dynam new nexsi apheresi
machin walk away call increas convict nexsi
valu proposit path exceed long rang plan lrp target
sustain growth beyond lrp
achiev revenu guidanc chri simon confid drive overal
growth target msd-hsd rang lrp assum haemonet
meet midpoint guidanc implic growth lrp
target
plasma growth recent market trend compani
deliv bottom end target rang even
adjust salin contract divestitur view
derisk assum plasma market growth slow new larg
hospit growth need reach bottom end
lrp target adjust orthopat divestitur
seem unlik given recent trend haemonet may miss lrp target
segment confid acceler mid-singl digit level
clear back safetrac tx teg trauma
indic approv yesterday
blood center declin would need sustain reach
bottom end target rang given
anniversari contract exit sign price stabil
appreci support
institut investor all-america
research survey request ballot
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
market like declin smaller suggest lrp target
achiev pleas see insid detail commentari hospit
blood center
ebit outlook continu look conserv manag reiter confid
meet lrp given complex reduct initi faster
plasma market growth profit target look conserv model
ebit lrp target note compani believ
still meet lrp expect without addit larg custom contract
model ebit year midpoint top-line growth organ
midpoint margin guidanc manag remain convinc
compani grow ep intermedi term assum stabl
tax share could indic ebit reinforc
compani meet beat lrp target without larg custom contract
assum greater drop-through remain save
factor faster plasma market growth exceed
nexsi transit still appear manag confid
nexsi nexlynk valu proposit confirm get
price premium origin intend consist dilig
model suggest date zero competit
loss compani data show nexsi deliv cost save
per liter reduct qualiti event overdraw underdraw
document error reduct donor process time ml
extra plasma yield per donat averag high end ml
label repres yield improv win win certain
custom move faster
haemonet buck price paradigm industri shift
util volume-bas price model premium nexsi
dilig suggest larg custom want ensur consist patient
experi believ nexsi superior across patient center
commentari consist real world dilig remain convinc
haemonet sign larg custom contract time model
contribut
commentari guidanc encourag conjunct plasma
divestitur referenc updat guidanc
reduc plasma report revenu growth corpor
report revenu growth organ revenu growth includ
plasma growth corpor growth margin guidanc
ep guidanc maintain north america
plasma dispos busi exclud liquid grew
underli growth busi strong last year exclud asset
estim ep tailwind divest busi unprofit
could note incorpor divestitur
adjust ep guidanc last week reinvest back busi
manag comfort ep guidanc note ep
top end start year flexibl
 continu comfort top end guidanc
rang ep
capit deploy third leg stool top-line margin
third leg select success devic stori balanc sheet deploy
haemonet alreadi begun flex muscl buyback compani
deploy februari buy-back outstand
share primarili execut asr manag
re-affirmed new buy-back outstand share
year still primarili meant off-set stock compens dilut view
repres addit lever flexibl manag meet
exceed ep target pertain continu like
hospit busi compani opportunist tuck-in deal
per manag commentari look complement current
product line particularli teg cardiolog trauma diagnost test
manag suggest asset valu rang
stori end nexsi get closer realiz
lrp investor begin look stori beyond nexsi
manag reiter increment nexsi platform
innov also note larger step chang still work
progress import continu believ plasma busi
grow hsd-ldd rang see oper incom capac
rate given addit opportun improv product come year
detail still limit time impress ceo chri simon
convict post-lrp busi
lrp target continu look conserv comfort
number reiter overweight view last week earn result
clear event guidanc came line investor expect
manag derisk origin lrp achiev current contract
could quantifi downsid risk ahead potenti larg contract time
later year remain confid nexsi remain primari driver
overweight thesi addit lever deploy
beyond nexsi includ teg oper leverag via tuck-in
balanc sheet deploy continu see path exceed
compani lrp model ebit compani
target price target reflect ebitda estim
includ quarter contribut remain overweight
hospit larg road less clear hospit segment
see risk lrp target impli growth
assum guidanc met vs averag growth manag
view hospit total address market salesforc ex-u
issu teg orthopat declin hamper hospit growth recent year mr
simon high convict compani acceler hospit busi
product teg new trauma indic safetrac tx cell saver elit
exit orthopat product line hospit busi revenu
extent growth rate doubl tripl would drive pt
corpor growth respect beyond expect supplement support
stabil price critic blood busi blood center end market continu
pressur effici hospit util blood reduc demand
custom prior manag action led price war whose effect still
seen sign stabil emerg along anniversari exit
certain blood contract could lead moder declin even
busi declin line averag declin
compani still meet lower end lrp target rang
importantli manag remain confid compani hold oper profit
dollar flat see busi way fund intern initi said
believ asset could divest note per reuter articl last week
freseniu reportedli talk potenti suitor sale blood
price target reflect ev/ebitda estim premium
upsid risk price target includ higher price benefit nexsi ii
identif addit cost opportun iii capit deploy downsid
risk includ nexsi disappoint ii cost save fail materi iii blood
bank slow materi iv teg disappoint
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report david
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
household member follow analyst strategist employe offic director anoth posit compani name within research
april benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur
within last month receiv compens invest bank servic axon modul
next month expect receiv intend seek compens invest bank servic
within last month receiv compens product servic invest bank servic abbott
within last month provid provid invest bank servic invest bank client relationship
follow compani alcon inc axon modul inc becton
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani becton
 co llc make market secur
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
